I-Daraxonrasib Ivunyiwe kwiCancer yePancreatic

IDaraxonrasib (iRasonque yiRevolution Medicines, Inc.), isithinteli sosapho lwe-RAS GTPase sivunyiwe ukuba sisetyenziswe kunyango lwabantu abadala abane-metastatic pancreatic ductal adenocarcinoma (mPDAC) ngomhla wama-26 ku-Agasti 2026 yi-FDA. I-Pancreatic ductal adenocarcinoma lolona hlobo luqhelekileyo lomhlaza we-pancreatic. Ukuvunywa kwe-daraxonrasib kunika aba baguli ukhetho olutsha lonyango. Unyango lwe-Tumour Treatment Fields (TTFields) ngokutshintshana kwamacandelo ombane lwavunywa ngaphambili kumhlaza we-pancreatic ophucukileyo wasekuhlaleni ngomhla we-12 kuFebruwari 2026.

Ukuvunywa kwe-daraxonrasib kwakusekelwe kwiziphumo ezivela kuvavanyo lweklinikhi lwesigaba sesi-3 olubandakanya abantu abadala abangama-500 abane-metastatic pancreatic adenocarcinoma ababesele benyangiwe, i-daraxonrasib ifunyenwe iphucula ukusinda okuphakathi ukuya kwiinyanga ezili-13.2 xa kuthelekiswa neenyanga ezi-6.7 ze-chemotherapy eqhelekileyo. 

Iproteni ye-RAS yeyona nto iphambili ekukhuleni kwethumba kwizigulane ezininzi ezine-pancreatic adenocarcinoma. I-Daraxonrasib ijolise koku. Idosi ecetyiswayo yi-300 mg ngomlomo kanye ngemini de isifo siqhubeke okanye sibe yingozi engamkelekanga, kwaye ivunyiwe ukunyanga abantu abadala abane-metastatic pancreatic adenocarcinoma abafumene ubuncinane unyango olunye lwangaphambili okanye abangengabo abafanelekileyo kwi-multiagent systemic therapy.

I-Pancreatic adenocarcinoma imalunga ne-3.2% yazo zonke iimeko zomhlaza, nangona kunjalo oku kubangela isabelo esiphezulu kakhulu sokufa komhlaza, ngenxa yokubhaqwa kade, ikhosi yesifo esiqatha, kunye neendlela zonyango ezinqongopheleyo. Unyango lwangoku lubonelela ngenzuzo encinci kwizigulane ezine-metastatic pancreatic ductal adenocarcinoma (mPDAC) ezinyangiweyo ngaphambili. Kwizigulane ezinjalo, unyango nge-daraxonrasib lukhokelele ekusindeni ixesha elide kakhulu kunye nokusinda okungenankqubela phambili kune-chemotherapy. 

Kumhlaza wepancreatic ophucukileyo apha ekhaya, unyango lweTumour Treating Fields (TTFields) ngokutshintshana kwamacandelo ombane lwavunywa yi-FDA kwangoko nge -12 kaFebruwari 2026. Oku kwakubalulekile kuba ulawulo lweklinikhi lomhlaza wepancreatic lunzima ngenxa yesifo esinganyangekiyo kunye nezinga eliphantsi lokusinda.

***

Iingxelo: 

1. Isaziso seendaba ze-FDA. I-FDA Ivuma Unyango Olujoliswe Kwiklasi Yokuqala Kwi-Metastatic Pancreatic Cancer. 26 Agasti 2026. Iyafumaneka apha https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer
2. I-FDA iyayivuma i-daraxonrasib kwi-metastatic pancreatic adenocarcinoma. Iyafumaneka kwi https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma
3. O'Reilly EM, okqhubekayo 2026. I-Daraxonrasib okanye i-Chemotherapy kwi-Metastatic Pancreatic Cancer eyayinyangwe ngaphambili. NEJM. 31 Meyi 2026. I-DOI: https://doi.org/10.1056/NEJMoa2605555
4. Isifundo seSigaba sesi-3 seDaraxonrasib (RMC-6236) kwizigulana ezineMetastatic Pancreatic Ductal Adenocarcinoma (PDAC) eyayinyangwe ngaphambili (RASolute 302). https://clinicaltrials.gov/study/NCT06625320
5. I-FDA News Release – I-FDA Ivuma Isixhobo Esiphambili Sohlobo Lwaso Sokunyanga Umhlaza Wepancreatic. Iposiwe nge-12 kaFebruwari 2026. Iyafumaneka apha https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer  

***

Amanqaku afanelekileyo: 

1. IiNdawo zokuNyanga iTumor (TTFields) zivunyiwe ukuba zinomhlaza wePancreatic (13 February 2026)

***